Lilly and OpenAI to Revolutionize Medicines to Treat Drug-Resistant Bacteria
Eli Lilly and Company has signed a collaboration deal with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Novel Antimicrobials | 26/06/2024 | By Aishwarya | 218
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy